Sheaff Brock Investment Advisors LLC Boosts Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Sheaff Brock Investment Advisors LLC grew its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 0.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,476 shares of the company’s stock after buying an additional 41 shares during the period. Sheaff Brock Investment Advisors LLC’s holdings in Medpace were worth $1,828,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of MEDP. DT Investment Partners LLC purchased a new stake in shares of Medpace during the second quarter valued at approximately $41,000. Ashton Thomas Securities LLC bought a new stake in Medpace during the 3rd quarter valued at approximately $37,000. Ashton Thomas Private Wealth LLC purchased a new position in Medpace during the 2nd quarter valued at approximately $52,000. EntryPoint Capital LLC purchased a new position in shares of Medpace in the 1st quarter worth approximately $54,000. Finally, Capital Performance Advisors LLP purchased a new position in shares of Medpace in the 3rd quarter worth approximately $46,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

MEDP has been the subject of several recent research reports. Baird R W lowered Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. William Blair restated an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. Redburn Atlantic initiated coverage on Medpace in a research note on Monday, October 14th. They issued a “buy” rating and a $404.00 price objective on the stock. Robert W. Baird cut Medpace from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $413.00 to $349.00 in a research report on Wednesday, October 23rd. Finally, TD Cowen lowered their price objective on Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $380.00.

Medpace Stock Performance

Shares of MEDP opened at $334.84 on Friday. Medpace Holdings, Inc. has a fifty-two week low of $268.80 and a fifty-two week high of $459.77. The stock has a fifty day moving average of $342.27 and a two-hundred day moving average of $376.61. The company has a market capitalization of $10.41 billion, a PE ratio of 29.32, a price-to-earnings-growth ratio of 2.00 and a beta of 1.37.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.24. The company had revenue of $533.32 million during the quarter, compared to analysts’ expectations of $540.99 million. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The firm’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same period in the prior year, the company posted $2.22 EPS. As a group, equities research analysts forecast that Medpace Holdings, Inc. will post 11.93 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.